268 related articles for article (PubMed ID: 26994504)
1. Association Of Bleeding Avoidance Strategies with age-related bleeding and In-hospital mortality in patients undergoing percutaneous coronary Interventions.
Khambatta S; Othman H; Seth M; Lalonde T; Rosman HS; Gurm HS; Mehta RH;
Cardiovasc Revasc Med; 2016 Jun; 17(4):233-40. PubMed ID: 26994504
[TBL] [Abstract][Full Text] [Related]
2. A regional pharmacoinvasive PCI strategy incorporating selected bleeding avoidance strategies.
Chava S; Raza S; El-Haddad MA; Priest J; Ashikaga T; Dauerman HL
Coron Artery Dis; 2015 Jan; 26(1):30-6. PubMed ID: 25279566
[TBL] [Abstract][Full Text] [Related]
3. The Impact of Bleeding Avoidance Strategies on Hospital-Level Variation in Bleeding Rates Following Percutaneous Coronary Intervention: Insights From the National Cardiovascular Data Registry CathPCI Registry.
Vora AN; Peterson ED; McCoy LA; Garratt KN; Kutcher MA; Marso SP; Roe MT; Messenger JC; Rao SV
JACC Cardiovasc Interv; 2016 Apr; 9(8):771-779. PubMed ID: 27101904
[TBL] [Abstract][Full Text] [Related]
4. The comparative safety and effectiveness of bivalirudin versus heparin monotherapy in patients on dialysis undergoing percutaneous coronary intervention: Insights from the Blue Cross Blue Shield of Michigan cardiovascular consortium.
Sukul D; Seth M; Schreiber T; Khandelwal A; Cannon LA; LaLonde TA; Gurm HS
Catheter Cardiovasc Interv; 2017 Nov; 90(5):724-732. PubMed ID: 28303632
[TBL] [Abstract][Full Text] [Related]
5. Bivalirudin for primary percutaneous coronary interventions: outcome assessment in the Ottawa STEMI registry.
Hibbert B; MacDougall A; Labinaz M; O'Brien ER; So DY; Dick A; Glover C; Froeschl M; Marquis JF; Wells GA; Blondeau M; Le May MR
Circ Cardiovasc Interv; 2012 Dec; 5(6):805-12. PubMed ID: 23149331
[TBL] [Abstract][Full Text] [Related]
6. Association between arterial access site and anticoagulation strategy on major bleeding and mortality: A historical cohort analysis in the Veteran population.
Bagai J; Little B; Banerjee S
Cardiovasc Revasc Med; 2018; 19(1 Pt B):95-101. PubMed ID: 28624360
[TBL] [Abstract][Full Text] [Related]
7. Differential Use and Impact of Bleeding Avoidance Strategies on Percutaneous Coronary Intervention-Related Bleeding Stratified by Predicted Risk.
Gluckman TJ; Wang L; Spinelli KJ; Petersen JL; Huang P; Amin A; Messenger JC; Rao SV
Circ Cardiovasc Interv; 2020 Jun; 13(6):e008702. PubMed ID: 32527190
[TBL] [Abstract][Full Text] [Related]
8. Combined Use of Bivalirudin and Radial Access in Acute Coronary Syndromes Is Not Superior to the Use of Either One Separately: Meta-Analysis of Randomized Controlled Trials.
Mina GS; Gobrial GF; Modi K; Dominic P
JACC Cardiovasc Interv; 2016 Aug; 9(15):1523-31. PubMed ID: 27491601
[TBL] [Abstract][Full Text] [Related]
9. Radial PCI and the obesity paradox: Insights from Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2).
McDonagh JR; Seth M; LaLonde TA; Khandewal AK; Wohns DH; Dixon SR; Gurm HS
Catheter Cardiovasc Interv; 2016 Feb; 87(2):211-9. PubMed ID: 26010906
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes.
Feldman DN; Minutello RM; Bergman G; Moussa I; Wong SC
Catheter Cardiovasc Interv; 2010 Oct; 76(4):513-24. PubMed ID: 20882655
[TBL] [Abstract][Full Text] [Related]
11. Arteriotomy closure device safety after percutaneous coronary intervention in the direct thrombin inhibitor era: a comparative study.
Theodos G; Raymond C; Becker MC; Thornton J; Ellis SG; Bhatt DL; Raymond RE
Catheter Cardiovasc Interv; 2013 Feb; 81(2):294-300. PubMed ID: 22826017
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of bivalirudin versus heparin in transradial coronary interventions.
Kheiri B; Rao SV; Osman M; Simpson TF; Barbarawi M; Zayed Y; Dhillon HN; Alkhouli M; Golwala H; Zahr F; Bhatt DL; Stone GW; Cigarroa JE
Catheter Cardiovasc Interv; 2020 Nov; 96(6):1240-1248. PubMed ID: 32091668
[TBL] [Abstract][Full Text] [Related]
13. Impact of worsening renal dysfunction on the comparative efficacy of bivalirudin and platelet glycoprotein IIb/IIIa inhibitors: insights from Blue Cross Blue Shield of Michigan Cardiovascular Consortium.
Perdoncin E; Zhang M; Riba A; LaLonde TA; Grines CL; Gurm HS
Circ Cardiovasc Interv; 2013 Dec; 6(6):688-93. PubMed ID: 24280966
[TBL] [Abstract][Full Text] [Related]
14. Impact of bivalirudin on in-hospital bleeding and six-month outcomes in octogenarians undergoing percutaneous coronary intervention.
Lemesle G; De Labriolle A; Bonello L; Syed A; Collins S; Maluenda G; Torguson R; Kaneshige K; Xue Z; Suddath WO; Satler LF; Kent KM; Lindsay J; Pichard AD; Waksman R
Catheter Cardiovasc Interv; 2009 Sep; 74(3):428-35. PubMed ID: 19360860
[TBL] [Abstract][Full Text] [Related]
15. Acute kidney injury after percutaneous coronary intervention: Rationale of the AKI-MATRIX (acute kidney injury-minimizing adverse hemorrhagic events by TRansradial access site and systemic implementation of angioX) sub-study.
Andò G; Cortese B; Frigoli E; Gagnor A; Garducci S; Briguori C; Rubartelli P; Calabrò P; Valgimigli M;
Catheter Cardiovasc Interv; 2015 Nov; 86(5):950-7. PubMed ID: 25854692
[TBL] [Abstract][Full Text] [Related]
16. Impact of anticoagulation strategy with bivalirudin or heparin on nonaccess site bleeding in percutaneous coronary interventions: A meta-analysis of randomized trials.
Verdoia M; Barbieri L; Parodi G; Bellandi B; Schaffer A; Suryapranata H; De Luca G
Catheter Cardiovasc Interv; 2017 Oct; 90(4):553-565. PubMed ID: 28471057
[TBL] [Abstract][Full Text] [Related]
17. Prediction of 1-year mortality and impact of bivalirudin therapy according to level of baseline risk: A patient-level pooled analysis from three randomized trials.
Yu J; Mehran R; Clayton T; Gibson CM; Brodie BR; Witzenbichler B; Lincoff AM; Deliargyris EN; Gersh BJ; Pocock SJ; Stone GW; Dangas GD
Catheter Cardiovasc Interv; 2016 Feb; 87(3):391-400. PubMed ID: 26624854
[TBL] [Abstract][Full Text] [Related]
18. Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trials.
Mehran R; Pocock S; Nikolsky E; Dangas GD; Clayton T; Claessen BE; Caixeta A; Feit F; Manoukian SV; White H; Bertrand M; Ohman EM; Parise H; Lansky AJ; Lincoff AM; Stone GW
JACC Cardiovasc Interv; 2011 Jun; 4(6):654-64. PubMed ID: 21700252
[TBL] [Abstract][Full Text] [Related]
19. Gender-based outcomes of bivalirudin versus heparin in patients undergoing percutaneous coronary interventions: Meta-analysis of randomized controlled trials.
Mina GS; Firouzbakht T; Modi K; Dominic P
Catheter Cardiovasc Interv; 2017 Nov; 90(5):735-742. PubMed ID: 28339139
[TBL] [Abstract][Full Text] [Related]
20. Femoral vascular closure device use, bivalirudin anticoagulation, and bleeding after primary angioplasty for STEMI: results from the HORIZONS-AMI trial.
Sanborn TA; Tomey MI; Mehran R; Généreux P; Witzenbichler B; Brener SJ; Kirtane AJ; McAndrew TC; Kornowski R; Dudek D; Nikolsky E; Stone GW
Catheter Cardiovasc Interv; 2015 Feb; 85(3):371-9. PubMed ID: 25179260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
